YH 42946
Alternative Names: YH-42946Latest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator Yuhan
- Class Antineoplastics
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 07 Oct 2024 Yuhan plans a phase I/II trial in Solid tumours and Non-small cell lung cancer (Metastatic disease, Late-stage disease, Second-line therapy or greater) in South Korea (PO) (NCT06616766)
- 07 Oct 2024 Preclinical trials in Solid tumours in South Korea (PO)
- 02 Oct 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA and South Korea (PO) (NCT06616766)